ストックスクリーナーアプリを入手
38.75
0.68%
0.26
前日終値:
$38.49
開ける：
$39.6
24時間の取引高:
613.00K
Relative Volume:
0.97
時価総額：
$2.31B
収益：
$45.48M
当期純損益:
$169.95M
株価収益率:
14.79
EPS:
2.62
ネットキャッシュフロー:
$230.85M
1週間 パフォーマンス:
+0.21%
1か月 パフォーマンス:
+1.71%
6か月 パフォーマンス:
-6.74%
1年 パフォーマンス:
+44.70%
1日の値動き範囲:
$38.44
$39.90
1週間の範囲:
$37.50
$39.90
52週間の値動き範囲:
$24.22
$48.89
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
名前
Protagonist Therapeutics Inc
セクター
電話
(510) 474-0170
住所
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
PTGX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
38.75 | 2.31B | 45.48M | 169.95M | 230.85M | 2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-06 | 開始されました | BMO Capital Markets | Outperform |
| 2024-12-06 | 開始されました | Goldman | Neutral |
| 2024-11-05 | 開始されました | Wedbush | Outperform |
| 2024-09-24 | 開始されました | TD Cowen | Buy |
| 2024-09-09 | 開始されました | Truist | Buy |
| 2023-10-30 | 開始されました | CapitalOne | Overweight |
| 2023-05-25 | 再開されました | Jefferies | Buy |
| 2022-08-25 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-02-11 | 開始されました | BTIG Research | Buy |
| 2021-10-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-10-11 | アップグレード | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-05-24 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-05-24 | 開始されました | Northland Capital | Outperform |
| 2021-01-06 | 開始されました | JP Morgan | Overweight |
| 2020-12-16 | 開始されました | Piper Sandler | Overweight |
| 2020-09-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-15 | 開始されました | Jefferies | Buy |
| 2020-05-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-07-08 | 開始されました | H.C. Wainwright | Buy |
| 2019-05-09 | アップグレード | Stifel | Hold → Buy |
| 2018-12-06 | 開始されました | Nomura | Buy |
| 2018-01-29 | 開始されました | Stifel | Buy |
| 2017-07-21 | 開始されました | BTIG Research | Buy |
すべてを表示
Protagonist Therapeutics Inc (PTGX) 最新ニュース
Investors in Protagonist Therapeutics (NASDAQ:PTGX) have seen enviable returns of 397% over the past five years - Yahoo Finance
Protagonist Therapeutics, Inc SEC 10-K Report - TradingView
Hussman Strategic Advisors Inc. Purchases New Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics: Q4 Earnings Snapshot - The Advocate
Protagonist Therapeutics (PTGX) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance
Earnings Flash (PTGX) Protagonist Therapeutics Posts Q4 License, Collaboration Revenue $170.6M - Marketscreener.com
Earnings Flash (PTGX) Protagonist Therapeutics Posts Q4 EPS $1.98 -February 21, 2025 at 07:14 am EST - Marketscreener.com
Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - ACCESS Newswire
AlphaCentric Advisors LLC Decreases Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics CEO Dinesh Patel sells shares worth $204,606 By Investing.com - Investing.com Australia
Protagonist Therapeutics (PTGX) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Stocks Generating Improved Relative Strength: Protagonist Therapeutics - MSN
Protagonist Therapeutics CEO Dinesh Patel sells shares worth $204,606 - Investing.com India
Protagonist Therapeutics CEO Sells Shares to Cover Tax Obligation - TradingView
BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment - GlobeNewswire Inc.
(PTGX) Proactive Strategies - Stock Traders Daily
Louisiana State Employees Retirement System Acquires 300 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics' SWOT analysis: stock poised for growth amid clinical milestones - Investing.com Australia
Protagonist Therapeutics’ SWOT analysis: stock poised for growth amid clinical milestones - Investing.com Nigeria
Jefferies maintains Buy on Protagonist Therapeutics, $57 target - MSN
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Yousif Capital Management LLC - Defense World
Will Weakness in Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Stock Prove Temporary Given Strong Fundamentals? - Simply Wall St
Analysts Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) PT at $56.00 - MarketBeat
Protagonist Therapeutics, Inc. (PTGX): A Cheap Biotech Stock to Invest In Now - Insider Monkey
Bleakley Financial Group LLC Has $246,000 Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives $56.00 Average PT from Brokerages - Defense World
10 Cheap Biotech Stocks to Invest in Now - Insider Monkey
Protagonist Therapeutics' (PTGX) Market Outperform Rating Reaffirmed at JMP Securities - MarketBeat
Taking the lead: Protagonist Therapeutics Inc (PTGX) - SETE News
HC Wainwright Reaffirms "Buy" Rating for Protagonist Therapeutics (NASDAQ:PTGX) - MarketBeat
Polycythemia Vera Market Predicted to See Upsurge Through 2034, - openPR
Protagonist Therapeutics’ (PTGX) “Buy” Rating Reiterated at HC Wainwright - Defense World
JMP Securities Reiterates “Market Outperform” Rating for Protagonist Therapeutics (NASDAQ:PTGX) - ETF Daily News
Protagonist Therapeutics’ (PTGX) “Market Outperform” Rating Reiterated at JMP Securities - Defense World
Protagonist Therapeutics (NASDAQ:PTGX) Given Market Outperform Rating at JMP Securities - Armenian Reporter
Objective long/short (PTGX) Report - Stock Traders Daily
Truist maintains Buy on Protagonist Therapeutics with $60 target - MSN
Truist maintains Buy on Protagonist Therapeutics with $60 target By Investing.com - Investing.com UK
JMP Securities maintains PTGX stock with $58 target - MSN
Caprock Group LLC Acquires New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Selling Buzz: Protagonist Therapeutics Inc [PTGX] Chief Medical Officer MOLINA ARTURO MD sells 26,000 shares of the company – Knox Daily - Knox Daily
Financial Metrics Check: Protagonist Therapeutics Inc (PTGX)’s Ratios for Trailing Twelve Months - The Dwinnex
Protagonist Therapeutics Inc (PTGX) deserves closer scrutiny - US Post News
Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - Defense World
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $53.00 - MarketBeat
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda - ACCESS Newswire
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Moody Aldrich Partners LLC - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Position Increased by Nisa Investment Advisors LLC - Defense World
Top Cancer Experts to Review Game-Changing Blood Disorder TreatmentHere's What's Coming - StockTitan
Protagonist Receives $34 Million from Warrant Exercises - ACCESS Newswire
Protagonist Therapeutics Inc (PTGX) 財務データ
収益
当期純利益
現金流量
EPS
Protagonist Therapeutics Inc (PTGX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| MOLINA ARTURO MD | Chief Medical Officer |
Nov 27 '24 |
Option Exercise |
8.04 |
26,000 |
209,040 |
62,444 |
| MOLINA ARTURO MD | Chief Medical Officer |
Nov 26 '24 |
Option Exercise |
8.04 |
5,529 |
44,453 |
51,973 |
| MOLINA ARTURO MD | Chief Medical Officer |
Nov 27 '24 |
Sale |
44.70 |
26,000 |
1,162,280 |
46,444 |
| MOLINA ARTURO MD | Chief Medical Officer |
Nov 26 '24 |
Sale |
45.60 |
5,529 |
252,122 |
46,444 |
| Gupta Suneel | Chief Development Officer |
Nov 25 '24 |
Option Exercise |
7.75 |
175,000 |
1,356,000 |
359,611 |
| Gupta Suneel | Chief Development Officer |
Nov 26 '24 |
Option Exercise |
12.17 |
30,450 |
370,576 |
286,174 |
| Gupta Suneel | Chief Development Officer |
Nov 25 '24 |
Sale |
46.04 |
103,437 |
4,762,239 |
256,174 |
| Gupta Suneel | Chief Development Officer |
Nov 26 '24 |
Sale |
45.50 |
19,191 |
873,190 |
266,983 |
| PATEL DINESH V PH D | President and CEO |
Nov 25 '24 |
Option Exercise |
21.58 |
1,727 |
37,269 |
429,935 |
| PATEL DINESH V PH D | President and CEO |
Nov 25 '24 |
Sale |
46.96 |
78,520 |
3,687,299 |
435,208 |
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):